See more : Silver Crest Acquisition Corporation (SLCRU) Income Statement Analysis – Financial Results
Complete financial analysis of Axonics, Inc. (AXNX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Axonics, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- Wrap Technologies, Inc. (WRAP) Income Statement Analysis – Financial Results
- ICARES Medicus, Inc. (6612.TWO) Income Statement Analysis – Financial Results
- Saudi Printing and Packaging Co. (4270.SR) Income Statement Analysis – Financial Results
- Nucleus Financial Group plc (NUC.L) Income Statement Analysis – Financial Results
- Wellfield Technologies Inc. (WFLD.V) Income Statement Analysis – Financial Results
Axonics, Inc. (AXNX)
About Axonics, Inc.
Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct salesforce and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 366.38M | 273.70M | 180.29M | 111.54M | 13.82M | 707.00K | 128.12K | 0.00 |
| Cost of Revenue | 91.83M | 76.04M | 64.57M | 44.44M | 6.49M | 356.00K | 117.94K | 625.12K |
| Gross Profit | 274.55M | 197.67M | 115.72M | 67.09M | 7.33M | 351.00K | 10.17K | -625.12K |
| Gross Profit Ratio | 74.94% | 72.22% | 64.18% | 60.15% | 53.04% | 49.65% | 7.94% | 0.00% |
| Research & Development | 34.89M | 34.41M | 37.30M | 29.17M | 20.18M | 19.40M | 12.33M | 12.51M |
| General & Administrative | 45.75M | 40.24M | 32.79M | 25.55M | 19.08M | 9.36M | 4.82M | 4.46M |
| Selling & Marketing | 189.56M | 156.02M | 105.79M | 66.13M | 48.67M | 3.72M | 1.03M | 516.08K |
| SG&A | 235.32M | 196.26M | 138.57M | 91.68M | 67.75M | 13.09M | 5.85M | 4.97M |
| Other Expenses | 14.96M | 9.38M | 7.24M | -412.15K | 0.00 | 0.00 | -20.82K | -291.00 |
| Operating Expenses | 270.20M | 240.05M | 183.11M | 120.85M | 87.93M | 32.49M | 18.19M | 17.48M |
| Cost & Expenses | 392.44M | 316.09M | 247.68M | 165.30M | 94.42M | 32.84M | 18.30M | 17.48M |
| Interest Income | 17.31M | 5.13M | 40.00K | 761.00K | 2.97M | 998.00K | 200.58K | 84.02K |
| Interest Expense | 0.00 | 2.43M | 7.43M | 1.87M | 2.31M | 1.34M | 22.00K | 0.00 |
| Depreciation & Amortization | 12.49M | 12.72M | 10.13M | 2.64M | 1.59M | 946.00K | 725.39K | 625.12K |
| EBITDA | 7.78M | -47.16M | -61.73M | -51.30M | -78.03M | -31.19M | -17.33M | -16.77M |
| EBITDA Ratio | 2.12% | -10.18% | -33.34% | -47.52% | -561.69% | -4,404.38% | -13,479.81% | 0.00% |
| Operating Income | -26.06M | -42.39M | -67.39M | -53.76M | -80.60M | -32.14M | -18.17M | -17.48M |
| Operating Income Ratio | -7.11% | -15.49% | -37.38% | -48.20% | -583.21% | -4,545.54% | -14,185.62% | 0.00% |
| Total Other Income/Expenses | 17.31M | 2.63M | -7.48M | -1.15M | 665.00K | -345.00K | 114.33K | 82.93K |
| Income Before Tax | -8.74M | -62.32M | -79.29M | -54.91M | -79.93M | -32.48M | -18.06M | -17.40M |
| Income Before Tax Ratio | -2.39% | -22.77% | -43.98% | -49.23% | -578.39% | -4,594.34% | -14,097.05% | 0.00% |
| Income Tax Expense | -2.66M | -2.62M | 782.00K | 1.00K | 1.00K | 1.00K | -20.82K | -291.00 |
| Net Income | -6.09M | -59.70M | -80.07M | -54.92M | -79.94M | -32.48M | -18.06M | -17.40M |
| Net Income Ratio | -1.66% | -21.81% | -44.41% | -49.24% | -578.40% | -4,594.48% | -14,097.05% | 0.00% |
| EPS | -0.12 | -1.28 | -1.86 | -1.48 | -2.80 | -4.64 | -0.97 | -0.95 |
| EPS Diluted | -0.12 | -1.28 | -1.86 | -1.48 | -2.80 | -4.64 | -0.97 | -0.95 |
| Weighted Avg Shares Out | 49.08M | 46.68M | 43.07M | 36.98M | 28.57M | 7.00M | 18.62M | 18.38M |
| Weighted Avg Shares Out (Dil) | 49.08M | 46.68M | 43.07M | 36.98M | 28.57M | 7.00M | 18.62M | 18.38M |
AXONICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Axonics, Inc. - AXNX
4 Stocks Backed by High Efficiency to Enrich Your Portfolio
Boston Scientific Announces Results for Fourth Quarter and Full Year 2023
AXONICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Axonics, Inc. - AXNX
Why Axonics Stock Soared Today
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Axonics, Inc.
Why Is Axonics (AXNX) Stock Up 20% Today?
Axonix Stock Hits 52-Week High on Buyout Buzz
Shareholder Alert: Ademi LLP investigates whether Axonics, Inc. has obtained a Fair Price in its transaction with Boston Scientific
AXNX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Axonics, Inc. Is Fair to Shareholders
Source: https://incomestatements.info
Category: Stock Reports